Please cite this article as: Zoltowska DM, Sadic E, Becoats K, Ghetiya S, Ali AA, Sattiraju S, Missov E. Cardiac papillary fibroelastoma. J Geriatr Cardiol 2021; 18(5): 346−351. DOI: 10.11909/j.issn.1671-5411.2021.05.009.
Citation: Please cite this article as: Zoltowska DM, Sadic E, Becoats K, Ghetiya S, Ali AA, Sattiraju S, Missov E. Cardiac papillary fibroelastoma. J Geriatr Cardiol 2021; 18(5): 346−351. DOI: 10.11909/j.issn.1671-5411.2021.05.009.
  • Papillary fibroelastoma (PFE) is a primary, histologically benign endocardial neoplasm. Though PFE has long been reported as the second most common primary cardiac neoplasm, it has since pulled ahead of cardiac myxomas, largely due to evolving cardiac imaging modalities. While PFEs are benign histologically, they have the potential for devastating clinical consequences, transient ischemic attack, stroke, myocardial infarction, syncope, pulmonary, and peripheral embolism. Despite increased detection rate, there remains uncertainty regarding etiology, exact prevalence, and clinical management of PFEs. This paucity of information is reflected by the lack of official guidelines on this matter. In this article, we aim to summarize the current state of understanding regarding PFE and discuss areas of ongoing controversy.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return